Laboratory of Toxicology, Department of Pharmacological Sciences, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy.
Toxicol Appl Pharmacol. 2012 Jan 15;258(2):248-55. doi: 10.1016/j.taap.2011.11.004. Epub 2011 Nov 18.
We have previously shown that PFOA and PFOS directly suppress cytokine secretion in immune cells, with different mechanisms of action. In particular, we have demonstrated a role for PPAR-α in PFOA-induced immunotoxicity, and that PFOS has an inhibitory effect on LPS-induced I-κB degradation. These studies investigate the immunomodulatory effects of four other PFCs, namely PFBS, PFOSA, PFDA, and fluorotelomer using in vitro assays. The release of the pro-inflammatory cytokines IL-6 and TNF-α was evaluated in lipolysaccharide (LPS)-stimulated human peripheral blood leukocytes (hPBL) and in the human promyelocytic cell line THP-1, while the release of IL-10 and IFN-γ was evaluated in phytohemagglutinin (PHA)-stimulated hPBL. All PFCs suppressed LPS-induced TNF-α production in hPBL and THP-1 cells, while IL-6 production was suppressed by PFOSA, PFOS, PFDA and fluorotelomer. PFBS, PFOSA, PFOS, PFDA and fluorotelomer inhibited PHA-induced IL-10 release, while IFN-γ secretion was affected by PFOSA, PFOS, PFDA and fluorotelomer. Leukocytes obtained from female donors appear to be more sensitive to the in vitro immunotoxic effects of PFCs when their responses are compared to the results obtained using leukocytes from male donors. Mechanistic investigations demonstrated that inhibition of TNF-α release in THP-1 cells occurred at the transcriptional level. All PFCs, including PFOA and PFOS, decreased LPS-induced NF-κB activation. With the exception of PFOA, none of the PFCs tested was able to activate PPARα driven transcription in transiently transfected THP-1 cells, excluding a role for PPARα in the immunomodulation observed. PFBS and PFDA prevented LPS-induced I-κB degradation. Overall, these studies suggest that PFCs affect NF-κB activation, which directly suppresses cytokine secretion by immune cells. Our results indicate that PFOA is the least active of the PFCs examined followed by PFBS, PFDA, PFOS, PFOSA and fluorotelomer.
我们之前已经表明,全氟辛烷磺酸(PFOA)和全氟辛基磺酸(PFOS)可通过不同的作用机制直接抑制免疫细胞中的细胞因子分泌。特别是,我们已经证明了过氧化物酶体增殖物激活受体-α(PPAR-α)在 PFOA 诱导的免疫毒性中的作用,并且 PFOS 对脂多糖(LPS)诱导的 I-κB 降解具有抑制作用。这些研究使用体外测定法研究了另外四种全氟化合物(PFBS、PFOSA、PFDA 和氟调聚物)的免疫调节作用。在脂多糖(LPS)刺激的人外周血白细胞(hPBL)和人早幼粒细胞白血病细胞系 THP-1 中评估了促炎细胞因子白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的释放,而在植物血球凝集素(PHA)刺激的 hPBL 中评估了白细胞介素-10(IL-10)和干扰素-γ(IFN-γ)的释放。所有 PFC 均抑制 LPS 诱导的 hPBL 和 THP-1 细胞中 TNF-α的产生,而 PFOSA、PFOS、PFDA 和氟调聚物抑制了 IL-6 的产生。PFBS、PFOSA、PFOS、PFDA 和氟调聚物抑制 PHA 诱导的 IL-10 释放,而 PFOSA、PFOS、PFDA 和氟调聚物影响 IFN-γ 的分泌。与使用男性供体获得的白细胞相比,当比较女性供体获得的白细胞的反应时,白细胞似乎对 PFC 的体外免疫毒性作用更为敏感。机制研究表明,THP-1 细胞中 TNF-α释放的抑制发生在转录水平。所有 PFC,包括 PFOA 和 PFOS,均降低 LPS 诱导的 NF-κB 活化。除 PFOA 外,测试的所有 PFC 均不能在瞬时转染的 THP-1 细胞中激活由 PPARα 驱动的转录,从而排除了 PPARα 在观察到的免疫调节中的作用。PFBS 和 PFDA 可防止 LPS 诱导的 I-κB 降解。总体而言,这些研究表明,PFC 会影响 NF-κB 的激活,从而直接抑制免疫细胞中的细胞因子分泌。我们的结果表明,在研究的 PFC 中,PFOA 的活性最低,其次是 PFBS、PFDA、PFOS、PFOSA 和氟调聚物。